What is the primary purpose of Evonik's $100 million investment in its Lafayette, Indiana facility?

The primary purpose is to modernize key equipment—including 100 m³ reactors and other critical systems—to enhance reliability, enable greater automation, and improve ergonomics and efficiency at the site, thereby strengthening Evonik’s cost leadership and supporting growing US-based demand for drug substance CDMO services.

Why is Evonik prioritizing its North American footprint—particularly the Tippecanoe site—for drug substance manufacturing?

Evonik is prioritizing North America due to geopolitical uncertainties underscoring the importance of Western-based production for critical drug substances and delivery technologies, coupled with rising molecular complexity in modern therapeutics; the Tippecanoe site is its second-largest US facility and one of the world’s largest API sites, featuring the industry’s biggest high-potency API operation with 170 m³ dedicated capacity and advanced containment systems.

Evonik to invest $100M in drug substance manufacturing site in Indiana

Jul 8, 2026

Evonik will invest $100 million over five years to modernize its Lafayette, Indiana facility, enhancing API manufacturing capabilities and automation. This strategic move aims to meet growing US demand for drug substance CDMO services amid rising molecular complexity.

chemweek

2026-07-08

Evonik to invest $100M in drug substance manufacturing site in Indiana

Evonik to invest $100M in drug substance manufacturing site in Indiana

FAQ